Humanin and MOTS-c at a glance
Both peptides belong to a small class called mitochondrial-derived peptides (MDPs), each translated from a short reading frame hidden inside a mitochondrial rRNA gene. Humanin comes from the 16S rRNA region. MOTS-c comes from the 12S rRNA region. Past that shared genetic address, the two molecules act on different cells through different receptors, and the published literature reflects it.
| Feature | Humanin | MOTS-c |
|---|---|---|
| Length | 24 amino acids | 16 amino acids |
| mtDNA origin | 16S rRNA gene | 12S rRNA gene |
| Discovery | 2001, Hashimoto et al., Osaka Bioscience Institute | 2015, Lee et al., USC Leonard Davis School of Gerontology |
| Primary mechanism | Bax binding; IGFBP-3 binding; gp130 receptor complex | Folate-AMPK pathway; nuclear translocation under stress |
| Main research focus | Apoptosis prevention in neurons, beta cells, germ cells | Skeletal muscle glucose metabolism, exercise response |
| Human trial status | No completed interventional trials | No completed interventional trials |
For a researcher choosing a starting point, target tissue is the practical dividing line. Humanin literature is almost entirely about blocking cell death in neurons, pancreatic beta cells, and germ cells. MOTS-c literature is almost entirely about skeletal muscle and whole-body glucose handling. The studies that put both peptides through the same assay, described further down, are still rare.
Where each peptide comes from
Hashimoto and colleagues at the Osaka Bioscience Institute found humanin in 2001 while screening a cDNA library built from the occipital lobe of a deceased Alzheimer's disease patient, a brain region without major amyloid pathology in that case. The translated product from a short open reading frame blocked neuronal death triggered by six different familial Alzheimer's disease gene mutations and by amyloid-beta peptide itself. The work appeared in the Proceedings of the National Academy of Sciences (Hashimoto Y et al., PNAS 2001;98(11):6336-6341), and the reading frame has since been confirmed across mammals.
MOTS-c followed fourteen years later. Lee, Zeng, Drew, Cohen, and colleagues at the USC Leonard Davis School of Gerontology described a 16-amino-acid peptide from the 12S rRNA region that improved insulin sensitivity and reduced fat accumulation in high-fat-diet mice, and restored insulin sensitivity in aged, insulin-resistant mice, with the effect disappearing when AMPK was knocked out (Lee C et al., Cell Metabolism 2015;21(3):443-454). Both peptides now sit inside a broader MDP family that also includes the SHLP1 through SHLP6 peptides, all encoded from the same rRNA regions of mitochondrial DNA.
How each one signals inside the cell
Humanin's anti-apoptotic effect runs through two intracellular interactions and one surface receptor. It binds Bax directly and blocks its move from the cytosol to the mitochondrial outer membrane, which stops cytochrome c release and halts the caspase cascade that follows (Guo B et al., Nature 2003;423:456-461). Separately, it binds IGFBP-3 and reduces its pro-apoptotic signaling. On the cell surface, humanin activates a receptor complex built from WSX-1, CNTF receptor alpha, and gp130, which phosphorylates STAT3, ERK1/2, and AKT.
MOTS-c works through a different toolkit entirely. It disrupts folate-dependent one-carbon metabolism, which limits purine synthesis, raises intracellular AMP, and activates AMPK, the enzyme that governs cellular energy balance. Under metabolic stress, MOTS-c also moves into the nucleus, where it drives NRF2-linked antioxidant gene expression.
Humanin's mechanisms are protein-protein interactions and a membrane receptor. MOTS-c's central mechanism is a metabolic enzyme cascade with a nuclear step. The two peptides share an origin but not a signaling strategy.
What happens when researchers test them side by side
Direct comparisons are uncommon, but two recent papers ran both peptides through the same experiment. Elhusseiny and colleagues treated primary human skeletal myotubes, grown from two young sedentary donors, with dexamethasone to induce muscle atrophy, then tested MOTS-c and the humanin analogue HNG at 10 micromolar each (Elhusseiny R et al., Physiological Reports 2026;14(4):e70791). Dexamethasone alone cut myotube area to 17.4 percent of baseline, against 34.5 percent in untreated controls.
MOTS-c co-treatment restored myotube area to 34.1 percent, blunted the dexamethasone-driven rise in MURF1 mRNA from 2.5-fold down to 1.7-fold, and raised Akt phosphorylation above control levels. Both MOTS-c and HNG suppressed the dexamethasone-induced rise in STAT3 activation. In this specific atrophy model, MOTS-c showed a broader protective effect than the humanin analogue, though the study drew on only three independent culture replicates per group.
Raijmakers and colleagues took a different angle, measuring both peptides from circulating monocytes in patients with Q fever fatigue syndrome (n=10), chronic fatigue syndrome (n=10), asymptomatic Q fever seropositive individuals (n=10), and healthy controls (n=10), after stimulating the cells with lipopolysaccharide (Raijmakers RPH et al., Journal of Translational Medicine 2019;17:157). Humanin production was lower in all three patient groups than in healthy controls (median 395 pg/mL in controls versus 371, 364, and 354 pg/mL across the three patient groups, p=0.05). MOTS-c gene expression was also reduced in patient groups, but MOTS-c peptide production itself showed no statistically significant difference between groups. In this fatigue-syndrome cohort, humanin tracked more consistently with clinical status than MOTS-c did.
Both papers work with small samples, two to three donor lines in the muscle study and ten patients per group in the fatigue study, so neither settles the comparison. What they show is that when the two peptides are tested under identical conditions, they do not always move together, and the tissue or condition under study changes which one looks more responsive.
Age, exercise, and the human data gap
Age-related decline has been measured for both peptides, though the details differ. D'Souza and colleagues found circulating MOTS-c 11 percent lower in men aged 45 to 55 and 21 percent lower in men aged 70 to 81, compared with men aged 18 to 30, even though skeletal muscle MOTS-c expression itself ran roughly 1.5-fold higher in both older groups (D'Souza RF et al., Aging 2020;12(6):5244-5258). The authors read this as a possible disconnect between how much MOTS-c muscle produces and how much of it reaches the bloodstream as people age.
A separate study found that a single bout of exercise raised MOTS-c 11.9-fold in skeletal muscle and 1.6-fold in plasma among healthy young men, with levels only partly back to baseline four hours later (Reynolds JC et al., Nature Communications 2021;12:470). The same paper dosed mice at three ages (2, 12, and 22 months) with MOTS-c and measured improved grip strength and treadmill endurance across all three groups, with the largest gains in the oldest animals.
Humanin's aging data leans more on lifespan than exercise. Overexpressing humanin in C. elegans extended lifespan by about 7 percent, from 17.7 to 19.0 days, in a manner dependent on the daf-16/FOXO pathway (Yen K et al., Aging 2020;12(12):11185-11199). Children of centenarians in the same study carried measurably higher circulating humanin than age-matched controls. Naked mole-rats, which barely show age-related decline in health, held stable humanin levels across two decades of life, while ordinary laboratory mice lost roughly 40 percent of their humanin over just 18 months.
Neither peptide has a completed trial administering it to human subjects as of September 2026. Everything above comes from cell culture, rodent dosing, or observational sampling of people who were not given either compound as an intervention.
Handling considerations for research use
Both peptides are supplied for research as lyophilized powder, usually as the acetate salt at 98 percent or higher purity, and both reconstitute in bacteriostatic water using the same technique. Cold-chain discipline matters more in Indonesia's climate than in a temperate lab, since heat and humidity above typical refrigeration ranges accelerate degradation once a vial leaves the freezer; the lyophilized peptide storage guide covers the specific temperature and humidity thresholds relevant to tropical storage.
The concentrations used in the studies above are cell culture doses, not injection amounts, and translating a micromolar cell culture figure into a bench-ready solution requires knowing the exact peptide mass on hand and the reconstitution volume chosen. The dosing calculator handles that conversion for a given vial. Both MOTS-c and humanin are listed in the compound catalog with current format and availability, and none of the figures in this article are a dosing recommendation for human use.